Through assessment of the diverse expression patterns of immune checkpoints, we noticed a significant enrichment of interactions, including TIGIT-PVR and LGALS9-HAVCR2 in baseline IPR tumors, suggesting novel immunotherapy targets for ESCC patients who may not benefit from NAT (Fig. 3J, K). This evidence concerns the gene PVR and esophageal squamous cell carcinoma.